

Filed via fax on July 10, 2009

*Customer No.: 20462
Confirmation No. 4857*

Attorney Docket No. P33159USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bamford et al.

Date: July 10, 2009

Serial No.: 10/539,385

Group Art Unit No.: 1624

Filed: June 16, 2005

Examiner: B.L. Coleman

For: Benzazepine Derivatives for the Treatment of Neurological Disorders

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FAX RECEIVED

JUL 10 2009

PETITION FOR WITHDRAWAL OF PATENT FROM ISSUE

OFFICE OF PETITIONS

Pursuant to 37 C.F.R. §1.313(c)(2), Applicants hereby respectfully petition the Commissioner to withdraw the application from issue. Please charge the required fee of \$130.00 for consideration of the Petition to Deposit Account No. 19-2570.

This request for withdrawal from issue of a prospective United States patent is made in conjunction with the attached Request for Continued Examination under 37 C.F.R. §1.114 to have new information considered. An Information Disclosure Statement, Form PTO 1449 listing 1 reference, 1 reference and an Amendment for Correction of Inventorship under 37 C.F.R. §1.48(b) are submitted herewith.

In view of the foregoing, Applicants respectfully request that this application be withdrawn from issue for consideration of the matter identified above.

07/14/2009 LDIEP1 00000001 192570 10539385
01 FC:1464 130.00 DA

Serial No.: 10/539,385
Group Art Unit No.: 1624

Please charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 19-2570.

Respectfully submitted,



Duke M. Fitch
Agent for Applicants
Registration No. 63,058

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5030
Facsimile (610) 270-5090